

Rabbit Anti-Collagen I antibody

SL10423R

Product Name Collagen I

Chinese Name I 型 Collagen protein/Collagen protein1/1 型 Collagen protein/I 型胶原 a1 抗体

Alias Collagen type I; Alpha 1 type I collagen; Alpha 2 type I collagen; COL1A1; COL1A2; Collagen polypeptide; Collagen I alpha 2 polypeptide; Collagen Of Skin Tendon And Bone; Collagen Type I alpha 1; Collagen type I alpha 2; OI4; Osteogenesis Imperfecta Type IV; Pro alpha 1(I) collagen; procollagen; CO1A1_HUMAN.

Research Area Tumour Cell biology immunology

Immunogen Species Rabbit

Clonality Polyclonal

React Species Human,Mouse,Rat

Applications WB=1:500-2000,IHC-P=1:500-1000,IHC-F=1:500-1000,ICC/IF=1:100-500,IF=1:500-1000,Flow cytometry
(Paraffin sections need antigen repair)
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.

Theoretical molecular weight 130kDa

Cellular localization Extracellular matrix Secretory protein

Form Liquid

Concentration 1mg/ml

immunogen KLH conjugated synthetic peptide derived from human Collagen I: 1051-1150/1464

Lsotype IgG

Purification affinity purified by Protein A

Buffer Solution 1M TBS(pH7.4) with 1% BSA, 3% Proclin300 and 50% Glycerol.

Storage Shipped at 4°C. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.

Attention This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

PubMed

[PubMed](#)

Collagens are highly conserved throughout evolution and are characterised by an uninterrupted 'triple repeat' that is a necessary part of the triple helical structure. Type I collagen (95 kDa) is found in the cornea, skin and tendon. Mutations in the encoding gene are associated with osteogenesis imperfecta, Ehlers-Danlos syndrome, and idiopathic osteoporosis. Reciprocal translocations between chromosomes 2 and 12, where this gene and the gene for Platelet-derived growth factor beta are located, are associated with a type of skin tumor called dermatofibrosarcoma protuberans, resulting from unregulated expression of the gene.

Function:

Type I collagen is a member of group I collagen (fibrillar forming collagen).

Subunit:

Trimers of one alpha 2(I) and two alpha 1(I) chains. Interacts with MRC2. Interacts with TRAM2.
Location : Secreted, extracellular space, extracellular matrix.

Subcellular Location:

Secreted, extracellular space, extracellular matrix.

Tissue Specificity:

Forms the fibrils of tendon, ligaments and bones. In bones the fibrils are mineralized with calcium phosphate.

Product Detail

Post-translational modifications:

Proline residues at the third position of the tripeptide repeating unit (G-X-P) are hydroxylated in alpha 1(I) chains. Proline residues at the second position of the tripeptide repeating unit (G-P-X) are hydroxylated in alpha 2(I) chains.

O-linked glycan consists of a Glc-Gal disaccharide bound to the oxygen atom of a post-translational asparagine hydroxyl group.

DISEASE:

Defects in COL1A1 are the cause of Caffey disease (CAFFD) [MIM:114000]; also known as infantile hyperostosis. Caffey disease is characterized by an infantile episode of massive subperiosteal new bone formation that typically involves the diaphyses of the long bones, mandible, and clavicles. The involved bones appear inflamed, with painful swelling and systemic fever often accompanying the illness. The bone lesions usually begin before 5 months of age and resolve before 2 years of age.

Defects in COL1A1 are a cause of Ehlers-Danlos syndrome type 1 (EDS1) [MIM:130000]; also known as Ehlers-Danlos syndrome gravis. EDS is a connective tissue disorder characterized by hyperextensibility of the skin, atrophic cutaneous scars due to tissue fragility and joint hyperlaxity. EDS1 is the severe form of Ehlers-Danlos syndrome.

Defects in COL1A1 are the cause of Ehlers-Danlos syndrome type 7A (EDS7A) [MIM:130060]; also known as autosomal dominant Ehlers-Danlos syndrome type VII. EDS is a connective tissue disorder characterized by hyperextensible skin, atrophic cutaneous scars due to tissue fragility and joint hyperlaxity. EDS7A is characterized by bilateral congenital hip dislocation, hyperlaxity of the joints, and recurrent partial dislocations.

Defects in COL1A1 are a cause of osteogenesis imperfecta type 1 (OI1) [MIM:166200]. A dominant form of osteogenesis imperfecta, a connective tissue disorder characterized by bone fragility and blue sclerae. Osteogenesis imperfecta type 1 is characterized by mild to moderate bone fragility, blue sclerae, and hearing loss.

non-deforming with normal height or mild short stature, and no dentinogenesis imperfecta. Defects in COL1A1 are a cause of osteogenesis imperfecta type 2 (OI2) [MIM:166210]; also known as osteogenesis imperfecta congenita. A connective tissue disorder characterized by bone fragility, perinatal fractures, severe bowing of long bones, undermineralization, and death in the perinatal period due to respiratory insufficiency.

Defects in COL1A1 are a cause of osteogenesis imperfecta type 3 (OI3) [MIM:259420]. A connective tissue disorder characterized by progressively deforming bones, very short stature, a triangular face, severe scleritis, and dentinogenesis imperfecta.

Defects in COL1A1 are a cause of osteogenesis imperfecta type 4 (OI4) [MIM:166220]; also known as osteogenesis imperfecta with normal sclerae. A connective tissue disorder characterized by moderate to severe short stature, mild to moderate scoliosis, grayish or white sclera and dentinogenesis imperfecta.

Genetic variations in COL1A1 are a cause of susceptibility to osteoporosis (OSTEOP) [MIM:166220]. Osteoporosis is characterized by reduced bone mass, disruption of bone microarchitecture without alteration in the composition of bone. Osteoporotic bones are more at risk of fracture.

Note=A chromosomal aberration involving COL1A1 is found in dermatofibrosarcoma protuberans. t(17;22)(q22;q13) with PDGF.

Similarity:

Belongs to the fibrillar collagen family.

Contains 1 fibrillar collagen NC1 domain.

Contains 1 VWFC domain.

SWISS:

P02452

Gene ID:

1277

Database links:

[Entrez Gene: 1277](#) Human

[Entrez Gene: 12842](#) Mouse

[Entrez Gene: 100008952](#) Rabbit

[Entrez Gene: 29393](#) Rat

[MIM: 120150](#) Human

[UniProt: P02453](#) Cow

[UniProt: O46392](#) Dog

[vissProt: P02452](#) Human

[vissProt: P11087](#) Mouse


[vissProt: P02454](#) Rat

[nigene: 172928](#) Human

[nigene: 277735](#) Mouse

[nigene: 107239](#) Rat

Product
Picture



Sample:

Ovary (Mouse) Lysate at 40 ug

NIH/3T3(huamn) Cell Lysate at 40 ug

Liver (Rat)Lysate at 40 ug

293T(huamn) Cell Lysate at 40 ug

A431(huamn) Cell Lysate at 40 ug


RAW264.7(huamn) Cell Lysate at 40 ug

Primary: Anti-Collagen I (SL10423R) at 1/300 dilution

Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution

Predicted band size: 95 kD

Observed band size: 110 kD



Sample:

Lane 1: Placenta (Mouse) Lysate at 40 ug


Lane 2: U-2OS (Human) Cell Lysate at 30 ug

Primary: Anti-Collagen I (SL10423R) at 1/1000 dilution

Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution

Predicted band size: 130'110 kD

Observed band size: 130 kD




Tissue/cell: human lung carcinoma; 4% Paraformaldehyde-fixed and paraffin-embedded;

Antigen retrieval: citrate buffer (1M, pH 6.0), Boiling bathing for 15min; Block endogenous


3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37°C for 2

Incubation: Anti-Collagen I Polyclonal Antibody, Unconjugated(SL10423R) 1:200, overnight

followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining



Paraformaldehyde-fixed, paraffin embedded (Mouse brain); Antigen retrieval by boiling in so buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 min buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (Collagen I) Polyclonal Unconjugated (SL10423R) at 1:400 overnight at 4°C, followed by operating according to SP (sp-0023) instructions and DAB staining.



Blank control:Hela.

Primary Antibody (green line): Rabbit Anti-Collagen I antibody (SL10423R)

Dilution: 1ug/Test;

Secondary Antibody : Goat anti-rabbit IgG-FITC

Dilution: 0.5ug/Test.

Protocol

The cells were fixed with 4% PFA (10min at room temperature)and then permeabilized with 95% methanol for 20 min at -20°C.The cells were then incubated in 5%BSA to block non-specific interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature.The secondary antibody used for 40 min at room temperature.Acquisition of 20,000 cells was performed.